MGX Metagenomi Therapeutics, Inc.

NASDAQ
$0.68

Metagenomi Therapeutics, Inc. (MGX) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.47 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.5% since its last earnings release on November 10, 2026.

Metagenomi Therapeutics Beat Consensus Estimates
Tuesday, November 10, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.47)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.73

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.